Across TCGA pan-cancer cohorts, GABRD Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GABRD data layer compared with 29 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher GABRD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GABRD expression acts as an unfavorable survival marker.
KICH, LUSC, and SARC are the cancer types where GABRD Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.